## Ciro Romano

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5175647/publications.pdf

Version: 2024-02-01

279798 233421 2,187 65 23 45 citations h-index g-index papers 66 66 66 3264 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Does poor glycaemic control affect the immunogenicity of the <scp>COVIDâ€19</scp> vaccination in patients with type <scp>2</scp> diabetes: The <scp>CAVEAT</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 160-165.	4.4	<b>7</b> 5
2	Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study. Clinical Infectious Diseases, 2022, 75, e403-e409.	5.8	40
3	Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 63-71.	0.5	8
4	Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Frontiers in Immunology, 2022, 13, 882064.	4.8	7
5	Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early) Tj ETQq1 1 0.78431	4 rgBT /(	Oveglock 10 To
6	Safety and Effectiveness of Dupilumab in Prurigo Nodularis. Journal of Investigational Allergology and Clinical Immunology, 2021, 31, 162-163.	1.3	14
7	Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opinion on Biological Therapy, 2021, 21, 661-674.	3.1	4
8	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2021, 15, 643-656.	3.0	8
9	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. Minerva Medica, 2021, 112, 246-254.	0.9	2
10	Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. Journal of Scleroderma and Related Disorders, 2021, 6, 256-263.	1.7	2
11	Detection of neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines. Annals of Allergy, Asthma and Immunology, 2021, 127, 499-501.	1.0	16
12	Authors' response. Annals of Allergy, Asthma and Immunology, 2021, 127, 703-704.	1.0	О
13	Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy. European Review for Medical and Pharmacological Sciences, 2021, 25, 3623-3631.	0.7	2
14	Choosing the most appropriate biologic therapy for Crohn's disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy, 2020, 20, 49-62.	3.1	6
15	Omalizumab as aÂlast resort therapy for intractable, severe chronic allergic rhinosinusitis. Allergo Journal International, 2019, 28, 99-102.	2.0	2
16	AB0648â€CORRELATIONS BETWEEN NEUTROPHIL/LYMPHOCYTE RATIO AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
17	Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. Clinical Rheumatology, 2018, 37, 1695-1700.	2.2	18
18	Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome. Journal of Clinical Rheumatology, 2018, 24, 281-285.	0.9	1

#	Article	IF	Citations
19	Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Review of Clinical Immunology, 2018, 14, 1089-1099.	3.0	11
20	Chronic Hepatitis C Virus Infection and Depression. Clinics in Liver Disease, 2017, 21, 517-534.	2.1	46
21	Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 1764-1774.	1.7	49
22	Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review. European Journal of Rheumatology, 2017, 4, 231-233.	0.6	5
23	Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report. European Annals of Allergy and Clinical Immunology, 2017, 49, 171.	1.0	1
24	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open, 2016, 1, e000038.	4.5	66
25	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. World Journal of Gastroenterology, 2015, 21, 2269.	3.3	134
26	Omalizumab for Difficult-to-Treat Dermatological Conditions: Clinical and Immunological Features from a Retrospective Real-Life Experience. Clinical Drug Investigation, 2015, 35, 159-168.	2.2	30
27	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence. Oncology Letters, 2015, 9, 542-550.	1.8	18
28	Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery, 2015, 158, 112-120.	1.9	71
29	Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. International Journal of Hematology, 2015, 101, 67-74.	1.6	10
30	Omalizumab therapy for children and adolescents with severe allergic asthma. Expert Review of Clinical Immunology, $2015$ , $11$ , $1309$ - $1319$ .	3.0	4
31	Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 2013, 17, 1809-1818.	1.7	45
32	Granulomatous Lobular Mastitis: Another Manifestation of Systemic Lupus Erythematosus?. Breast Journal, 2013, 19, 331-332.	1.0	8
33	Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World Journal of Hepatology, 2013, 5, 528.	2.0	178
34	Clinically-Irrelevant Positivity for Serum Proteinase 3-ANCA in HIV Disease. International Journal of Immunopathology and Pharmacology, 2013, 26, 957-959.	2.1	5
35	Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery. Journal of Clinical Immunology, 2011, 31, 1095-1104.	3.8	38
36	A subtle case of iron-deficiency anemia. Internal and Emergency Medicine, 2011, 6, 191-192.	2.0	0

#	Article	IF	CITATIONS
37	Lupus Mastitis in Systemic Lupus Erythematosus: A Rare Condition Requiring a Minimally Invasive Diagnostic Approach. International Journal of Immunopathology and Pharmacology, 2011, 24, 1125-1129.	2.1	7
38	Maintenance of Remission With Low-Dose Omalizumab in Long-Lasting, Refractory Chronic Urticaria. Annals of Allergy, Asthma and Immunology, 2010, 104, 95-97.	1.0	32
39	A Scleroderma-Like Cutaneous Syndrome Associated With a Marked Th2-Type Immune Response Occurring After a Prosthetic Joint Implant. Journal of Clinical Rheumatology, 2009, 15, 133-137.	0.9	3
40	T-2 toxin immunotoxicity on human B and T lymphoid cell lines. Toxicology, 2005, 210, 81-91.	4.2	58
41	Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunology Letters, 2005, 97, 131-139.	2.5	19
42	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. Clinical Cancer Research, 2004, 10, 3490-3499.	7.0	103
43	Prognostic Value of p27, p53, and Vascular Endothelial Growth Factor in Dukes A and B Colon Cancer Patients Undergoing Potentially Curative Surgery. Diseases of the Colon and Rectum, 2004, 47, 1904-1914.	1.3	30
44	Primary cardiac T-cell lymphoma. Annals of Hematology, 2004, 83, 450-454.	1.8	46
45	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 2004, 100, 270-278.	4.1	100
46	Normal Interleukin-10 Serum Level Opposed to High Serum Levels of Carbohydrate Antigen 19-9 and Cancer Antigens 125 and 50 in a Case of True Splenic Cyst. Archives of Medical Research, 2003, 34, 145-148.	3.3	12
47	Effects of Stress Hyperglycemia on Acute Myocardial Infarction: Role of inflammatory immune process in functional cardiac outcome. Diabetes Care, 2003, 26, 3129-3135.	8.6	153
48	Effects of Preactivated Autologous T Lymphocytes on CD80, CD86 and CD95 Expression by Chronic Lymphocytic Leukemia B Cells. Leukemia and Lymphoma, 2003, 44, 1963-1971.	1.3	14
49	A True Splenic Cyst Producing Carbohydrate Antigen 19-9 and Cancer Antigens 50 and 125, but Not Interleukin 10. Digestive Surgery, 2003, 20, 71-74.	1.2	7
50	Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells. Oncology Reports, 2003, 10, 653-8.	2.6	4
51	Efficacy of L-Carnitine in Reducing Hyperammonaemia and Improving Neuropsychological Test Performance in Patients with Hepatic Cirrhosis. Clinical Drug Investigation, 2002, 22, 7-14.	2.2	11
52	Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery. Clinical Immunology, 2002, 102, 169-178.	3.2	196
53	Relationship between total and allergen-specific IgE serum levels and presence of symptoms in farm workers sensitized to Tetranychus urticae. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 1044-1047.	5.7	7
54	Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and Outcome. Journal of Interferon and Cytokine Research, 2002, 22, 473-482.	1.2	60

#	Article	IF	CITATION
55	Altered constitutive and activation-induced expression of CD95 by B- and T-cells in B-cell chronic lymphocytic leukemia. Haematologica, 2002, 87, 325-7.	3.5	2
56	Long-term absence of sensitization to mepivacaine as assessed by a diagnostic protocol including patch testing. Clinical and Experimental Allergy, 2001, 31, 1762-1770.	2.9	15
57	Epidemiology of allergic occupational diseases induced by Tetranychus urticae in greenhouse and open-field farmers living in a temperate climate area. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1157-1163.	5.7	9
58	Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. Journal of Interferon and Cytokine Research, 2001, 21, 45-52.	1.2	76
59	Semiallogeneic Cell Hybrids as Therapeutic Vaccines for Cancer. Journal of Immunotherapy, 2000, 23, 246-254.	2.4	16
60	Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunology, Immunotherapy, 2000, 49, 530-536.	4.2	51
61	Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients. Chest, 2000, 117, 365-373.	0.8	139
62	Lymphoblastoid $\hat{l}$ ±-IFN, leukocytic $\hat{l}$ ±-IFN and natural $\hat{l}$ 2-IFN in the treatment of chronic hepatitis C: a clinical comparison of 150 cases. Hepatology Research, 1999, 15, 225-237.	3.4	3
63	Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. , 1999, 86, 1936-1943.		<b>7</b> 5
64	Serum interleukinâ€10 levels in patients with advanced gastrointestinal malignancies. Cancer, 1999, 86, 1936-1943.	4.1	4
65	Eosinophilia triggered by $\hat{I}^2$ -interferon therapy for chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 1997, 9, 909-911.	1.6	7